Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Cabozantinib is an inhibitor of tyrosine kinases, including MET,vascular endothelial growth factor receptor, AXLand RET. This multi-cohort phase II randomised discontinuation trialexplored anticancer activity of cabozantinib in nine tumour types.Cabozantinib was administered (100mg, once daily) to patients with advanced, recurrentor metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase.A total of 526 patients were enroll... Mehr ...

Volltext
Verfasser: Schöffski, Patrick
Gordon, Michael
Smith, David C
Kurzrock, Razelle
Daud, Adil
Vogelzang, Nicholas J
Lee, Yihua
Scheffold, Christian
Shapiro, Geoffrey I
Dokumenttyp: Artikel
Erscheinungsdatum: 2017
Verlag/Hrsg.: eScholarship
University of California
Schlagwörter: Biomedical and Clinical Sciences / Clinical Sciences / Oncology and Carcinogenesis / Cancer / Clinical Trials and Supportive Activities / Clinical Research / Rare Diseases / Evaluation of treatments and therapeutic interventions / 6.1 Pharmaceuticals / Anilides / Antineoplastic Agents / Belgium / Disease Progression / Disease-Free Survival / Drug Administration Schedule / Early Termination of Clinical Trials / Female / Humans / Israel / Kaplan-Meier Estimate / Male / Neoplasms / Protein Kinase Inhibitors / Pyridines / Taiwan / Time Factors / Treatment Outcome / United States / Cabozantinib / Vascular endothelial growth factor receptor / Solid tumour / Objective response rate / Progression-free survival / Randomised discontinuation trial / Public Health and Health Services / Oncology & Carcinogenesis
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-27356263
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://escholarship.org/uc/item/75w037dr